Armata PharmaceuticalsARMP +0.17%27 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates ARMP with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 843 Biotechnology companies, Armata Pharmaceuticals ranks worse than 118623.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Armata Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Armata Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
Armata Pharmaceuticals (AMEX:ARMP) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Armata Pharmaceuticals Receivables Turnover Related Terms
Armata Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Armata Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARMP vs NAGE, ALXO, LYEL: Receivables Turnover Comparison
For the Biotechnology subindustry, Armata Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Armata Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals (ARMP) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Armata Pharmaceuticals and its competitors. According to the industry distribution chart, Armata Pharmaceuticals ranks #999999 out of 843 companies in the Biotechnology industry.
Is Armata Pharmaceuticals' Receivables Turnover too high?
Armata Pharmaceuticals' current Receivables Turnover is 0.00. Based on the distribution chart, Armata Pharmaceuticals ranks #999999 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Armata Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' Receivables Turnover compare to NAGE and ALXO?
According to the Biotechnology industry distribution chart, Armata Pharmaceuticals ranks #999999 out of 843 companies for Receivables Turnover. This places Armata Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Armata Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Armata Pharmaceuticals's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (ARMP) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Armata Pharmaceuticals' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Armata Pharmaceuticals (ARMP), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
27GF Score
Get the complete analysis for ARMP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARMP has been successfully added to your 
